Cationic Antiseptic Compositions for Mucosal Tissue
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antimicrobial agents face challenges such as resistance development, irritation issues, and ineffectiveness on moist tissues like the nasal passages and wounds, particularly in decolonizing Staphylococcus aureus and treating infections without causing clinical resistance or tissue damage.
Innovation Solution
Development of antimicrobial compositions containing cationic antiseptics like chlorhexidine and silver complexes, combined with hydrophobic phases and surfactants, which provide broad-spectrum activity, reduce resistance potential, and minimize irritation by maintaining substantivity on tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotics are used for nasal decolonization, then antimicrobial activity is achieved, but resistance development occurs
Solution Approach 1:
The patent changes the chemical parameter from antibiotic to cationic antiseptic (quaternary ammonium compound), fundamentally altering the mechanism of action from specific metabolic pathway inhibition to nonspecific cell membrane disruption, thereby eliminating resistance development while maintaining antimicrobial activity
Solution Approach 2:
The patent combines cationic antiseptic with hydrophobic phase and surfactant to create a composite formulation that enhances substantivity to moist tissues while maintaining broad-spectrum antimicrobial activity and minimizing irritation
2Reliability
If antiseptics are used at high concentrations, then broad-spectrum antimicrobial activity is achieved, but tissue irritation increases
Solution Approach 1:
The patent optimizes the concentration parameter to below 1% (typically 0.01-0.5%), which is lower than conventional antiseptic formulations, thereby reducing tissue irritation while maintaining effective antimicrobial activity through enhanced substantivity
Solution Approach 2:
The patent introduces hydrophobic phase and surfactant as intermediaries that facilitate controlled delivery of the cationic antiseptic to moist tissues, enhancing substantivity and allowing lower concentrations to achieve prolonged effect without irritation
3Reliability
If conventional antiseptics are applied to moist tissues, then antimicrobial activity is achieved, but substantivity is reduced
Solution Approach 1:
The patent creates a composite formulation where the cationic antiseptic is combined with hydrophobic phase and surfactant, which together enhance substantivity to moist tissues by reducing washoff and improving adhesion, thereby prolonging duration of action
Solution Approach 2:
The hydrophobic phase forms a thin film on moist tissues that acts as a reservoir for the cationic antiseptic, allowing sustained release and maintaining substantivity even in the presence of moisture and secretions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions effectively reduce microbial loads on mucosal tissues and wounds with low resistance potential, providing prolonged antimicrobial activity and minimal irritation, suitable for repeated use without generating clinical resistance.
Implementation Method 1
They tend to have broader spectrum of antimicrobial activity and often act by nonspecific means such as disruption of cell membranes
Implementation Method 2
compositions containing a cationic antiseptic and a surfactant
Implementation Method 3
The compositions effectively reduce microbial loads on mucosal tissues and wounds with low resistance potential, providing prolonged antimicrobial activity
Data Source
AI summary
Antimicrobial compositions, especially those useful when applied topically, particularly to mucosal tissues (i.e., mucous membranes), including a cationic antiseptic such as biguanides and bisbiguanides such as chlorhexidine and its various salts including but not limited to the digluconate, diacetate, dimethosulfate, and dilactate salts; polymeric quaternary ammonium compounds such as polyhexamethylenebiguanide; silver and various silver complexes; small molecule quaternary ammonium compounds such as benzalkoium chloride and alkyl substituted derivatives; di-long chain alkyl (C8-C18) quaternary ammonium compounds; cetylpyridinium halides and their derivatives; benzethonium chloride and its alkyl substituted derivatives; and octenidine. The compositions can also include an enhancer component, a surfactant, a hydrophobic component, and/or a hydrophilic component. Such compositions provide effective topical antimicrobial activity and are accordingly useful in the treatment and/or prevention of conditions that are caused, or aggravated by, microorganisms (including viruses).